Abstract
Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consider how this complexity could influence therapeutic design strategies.
| Original language | English |
|---|---|
| Pages (from-to) | 450-453 |
| Number of pages | 4 |
| Journal | Trends in Cancer |
| Volume | 6 |
| Issue number | 6 |
| Early online date | 16 Mar 2020 |
| DOIs | |
| Publication status | Published - Jun 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Translin-Trax
- Dicer
- drug development
- miRNA
- DNA repair
Fingerprint
Dive into the research topics of 'Translin-Trax: Considerations for Oncological Therapeutic Targeting'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver